Anavex Life Sciences Corp. (AVXL) stock
AVXLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 28, 2026Score 6/30
$0.72−0.02 (-2.78%)
Close on Nov 18, 2026Market cap $66.69MP/E –Yield –
Anavex Life Sciences enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Anavex Life Sciences's enterprise value was -$20.07M on Nov 11, 2026, against $229.36M a year earlier. Over the last 5 years it ranged from -$20.07M to $1.16B, with a median of $508.48M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | -$20.07M | -109.7% |
| 2025 | Dec 31, 2025 | $205.96M | -73.5% |
| 2024 | Dec 31, 2024 | $778.52M | +27.0% |
| 2023 | Dec 29, 2023 | $613.02M | +7.1% |
| 2022 | Dec 30, 2022 | $572.59M | -50.8% |
| 2021 | Dec 31, 2021 | $1.16B | +280.8% |
| 2020 | Dec 31, 2020 | $305.80M | +167.8% |
| 2019 | Dec 31, 2019 | $114.18M | +134.3% |
| 2018 | Dec 31, 2018 | $48.73M | -56.5% |
| 2017 | Dec 29, 2017 | $112.08M | -16.4% |
| 2016 | Dec 30, 2016 | $134.04M | -17.9% |
| 2015 | Dec 31, 2015 | $163.20M | +2097.7% |
| 2014 | Dec 31, 2014 | $7.43M | -17.2% |
| 2013 | Dec 31, 2013 | $8.96M | -62.5% |
| 2012 | Dec 31, 2012 | $23.88M | -26.0% |
| 2011 | Dec 30, 2011 | $32.28M | -62.3% |
| 2010 | Dec 31, 2010 | $85.57M | – |
See a number that looks wrong?